Learning points
• Clinicians must have an index of suspicion for antibody-mediated rejection in late post-transplant patients presenting with symptoms that could indicate graft dysfunction.
• Non-invasive imaging tests frequently used in routine screening protocols of otherwise low-risk late post-transplant patients may miss this diagnosis.
• Despite aggressive immunotherapies and histological resolution this diagnosis can portend a very poor prognosis with progressive coronary artery vasculopathy and graft dysfunction.
Introduction
Late antibody-mediated rejection [AMR, defined as allograft dysfunction with serologic evidence of donor-specific antibodies (DSAs) and endomyocardial biopsy features occurring over 1 year post-transplant 1 ] is rare, but very late AMR (over 10 years post-transplant) is very rare. 2, 3 It is associated with high mortality, graft dysfunction, and fulminant coronary artery vasculopathy (CAV) 2 and should remain in the differential for late graft dysfunction.
Timeline

Case presentation
A 57-year-old woman 16 years of post-heart transplant presented in January 2017 with several weeks of back and chest pain, shortness of breath, vomiting, generalized fatigue, and 10 pound weight gain. Her post-transplant course had been uneventful, and she had been treated with mycophenolate mofetil (MMF) and cyclosporine since transplant. Her last protocol-driven screening biopsy 12 years prior to presentation demonstrated 1B rejection. Three months prior to her presentation she had a routine exercise nuclear stress test suggesting normal graft function. Her most recent screening coronary angiogram in 2008 showed no coronary artery disease.
On exam heart rate was 110 b.p.m., with blood pressure 115/78 and she had pulmonary and peripheral oedema. Laboratory testing revealed mildly elevated LDH and troponin-I levels, significantly elevated N-terminal prohormone of brain natriuretic peptide levels (3763 pg/mL, normal 0-100 pg/mL), while other lab studies were unremarkable. An electrocardiogram revealed no ischaemic changes. A transthoracic echocardiogram demonstrated intact biventricular function without wall motion abnormalities, but increased left ventricular wall thickness ( Figure 1 ). Cardiac magnetic resonance imaging with gadolinium was not performed because of concern for renal dysfunction. Right heart catheterization was significant for elevated mean right atrial pressure (20 mmHg), mean pulmonary artery pressure (27 mmHg), and mean wedge pressure (20 mmHg) with reduced cardiac index [Fick CI 2.18 L/(m 2 *min)]. Left heart catheterization ( Figure 2A and B) revealed a 40% stenosis in the mid and 60% in the distal left anterior descending (LAD) artery concerning for CAV. No other abnormalities were noted in the coronary arteries and intravascular ultrasound was not performed to avoid heparin exposure for the patient given the suspicion of rejection and urgent need for endomyocardial biopsy. Endomyocardial biopsy ( Figure 3A ) revealed no signs of cellular rejection (Grade 0), but with prominent blue staining of endothelial cells suggestive of endothelial activation. Multiple MHC Class 1 and Class 2 DSAs were positive, with mean fluorescence intensity >3000 ( Table 1) . Immunohistochemistry for C4d showed positive capillary staining consistent with AMR ( Figure  3B ). Treatment for AMR was initiated with steroids and plasmapharesis, followed by rituximab. Due to persistent symptoms and DSAs, she was later treated with bortezomib. Immunosuppression was transitioned from cyclosporine to tacrolimus with ongoing prednisone and MMF. Her symptoms resolved with these interventions suggesting that AMR was the aetiology of her initial presentation. In May 2017, repeat endocardial biopsy demonstrated negative immunohistochemistry with C4d after treatment with no staining in capillaries. 2001 Patient undergoes successful heart transplant.
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Standard, protocol-driven endomyocardial biopsies show no evidence of rejection.
2013-16
Protocol driven screening myocardial perfusion scans demonstrate no evidence of coronary artery disease In July 2017, she was hospitalized with enterotoxigenic Escherichia coli infection requiring azithromycin. Screening myocardial perfusion imaging performed subsequently demonstrated a new large, severe, predominantly fixed distal anterior and apical wall defect compatible with infarct with mild peri-infarct ischaemia, as well as a medium sized, mild inferior lateral wall defect compatible with infarct. Left heart catheterization found progressive diffuse CAV with worsened involvement of the distal LAD, mid circumflex, first obtuse marginal, and right posterior descending artery ( Figure 2C-F) . No discrete lesions were amenable to percutaneous intervention. In response, her immunosuppression changed to everolimus, tacrolimus, and prednisone. In November 2017, she presented with an acute gout flare, as well as volume overload. Donor-specific antibodies checked at that time remained positive and demonstrated only two MHC Class 1 antigens greater than 3000. Repeat endomyocardial biopsy demonstrated no evidence of cellular rejection and negative immunohistochemistry staining for C4d. She presented to hospital again in December 2017 with oral HSV infection and volume overload, this time in the setting of end-stage renal disease (ESRD) attributed to tacrolimus toxicity and cardiorenal syndrome that has required ongoing treatment with haemodialysis. Because of renal dysfunction attributed in part to tacrolimus, her immunosuppression was changed at that time to everolimus and prednisone, on which she has remained clinically stable with New York Heart Association Class I-II symptoms over the past few months. As of February 2018, her left ventricular function improved to normal and no wall motion abnormalities were noted on echocardiogram. Going forward, her surveillance will include clinical follow-up and serial echocardiograms every 6 months.
Discussion
As was done for our patient, treatment for patients with late AMR and CAV includes transition to a new immunosuppressive agent, as well as plasmapheresis, immunotherapy, and steroids. 1 Percutaneous intervention is carried out on amenable coronary lesions. Our patient had a low-risk screening myocardial perfusion scan just 3 months prior to presentation in heart failure with AMR demonstrating the poor sensitivity of non-invasive tests for detecting AMR, 4 and by extension late AMR. Screening protocols for late AMR are not established. Our patient's slowly increasing left ventricular wall thicknesses on previous routine echocardiograms may have been a clue as this finding has been linked to increased mortality and CAV, 5 however, an association with late AMR has not been established. Anti-endothelial, non-HLA antibodies associated with CMV infection have been implicated in CAV and rejection in heart transplant patients, 1 and our patient did have elevated CMV DNA copies (albeit below the level that could be accurately quantified) at the time of her presentation with renal failure in December 2017. The exposure to several infections during 2017 could have led to such an immune cascade and contributed to her clinical course, although she did not have further graft dysfunction in 2017 at the time of this DNA result.
Despite aggressive AMR management, DSAs and symptoms persisted and CAV progressed. Multiple infections complicated our patient's immunosuppressive treatment and toxicity likely contributed to her development of ESRD.
Conclusions
This case of AMR greater than 10 years post-heart transplantation highlights that clinicians must have an index of suspicion of this diagnosis in late post-transplant patients with unclear cardiac symptoms as non-invasive tests frequently used in screening protocols may miss this diagnosis. Clinical deterioration of this patient after initiation of treatment highlights that further investigation is required to define optimal management. 
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